publication . Article . 2014

Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial

P. Arcaina; J. Murillas; Esteban Martínez; Javier Murillas; D. Dalmau; M. Cairó; Ana González-Cordón; Joaquim Peraire; J. Peraire; J.R. Arribas; ...
Open Access English
  • Published: 10 Nov 2014
  • Publisher: Oxford University Press
  • Country: Spain
This article has been accepted for publication in Clinical Infectious Diseases ©2014 The Authors .Published by Oxford University Press on Clinical Infectious Disease 60.5. DOI: 10.1093/cid/ciu898 Background. It is unclear whether metabolic or body composition effects may differ between protease inhibitor-based regimens recommended for initial treatment of HIV infection. Methods. ATADAR is a phase IV, open-label, multicenter randomized clinical trial. Stable antiretroviral-naive HIV-infected adults were randomly assigned to atazanavir/ritonavir 300/100 mg or darunavir/ritonavir 800/100 mg in combination with tenofovir/emtricitabine daily. Pre-defined end-points w...
Medical Subject Headings: virus diseasesimmune system diseases
free text keywords: Antiretroviral therapy, Medicina, Microbiology (medical), Infectious Diseases, Proteolytic enzymes, Ritonavir, medicine.drug, medicine, Protease, medicine.medical_treatment, Darunavir, HIV Protease Inhibitor, Immunology, Randomized controlled trial, law.invention, law, Internal medicine, medicine.medical_specialty, Infectious disease (medical specialty), Surrogate endpoint, business.industry, business
Any information missing or wrong?Report an Issue